Bulk Quote Inquiry

COV-VM1RM-100μg / Inquiry

COV-VM1RM-500μg / Inquiry

COV-VM1RM-1mg / Inquiry

SARS-COV-2 Spike RBD ( N501Y,K417N,E484K ) Protein

Product Info
Source

Recombinant SARS-COV-2 Spike RBD ( N501Y,K417N,E484K ) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Arg319-Phe541(N501Y,K417N,E484K).[Accession | QHD43416.1]

Molecular Weight

The protein has a predicted MW of 26.2 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Tris-Bis PAGE result.

Endotoxin

Less than 1EU per μg by the LAL method.

Purity

> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.

Reconstitution

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage

The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

SARS-COV-2 Spike RBD ( N501Y,K417N,E484K ) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of SARS-COV-2 Spike RBD ( N501Y,K417N,E484K ) is greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized SARS-COV-2 Spike RBD (N501Y,K417N,E484K) at 0.5μg/ml (100ul/Well) on the plate. Dose response curve for Human ACE2, hFc Tag with the EC50 of 0.02μg/ml determined by ELISA.

Background

SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells. It has been reported that the UK and South African strains may have higher transmission capabilities, eventually in part due to amino acid substitutions on the SARS-CoV-2 Spike protein.The results of a study show the N501Y replacement in this region of the interface (present in both the UK and South African strains) should be favorable for the interaction with ACE2, while the K417N and E484K substitutions (South African strain) would seem neutral or even unfavorable.

Synonyms

S protein RBD;Spike glycoprotein Receptor-binding domain;S glycoprotein RBD;Spike protein RBD

References

(1)Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol Sci. 2021 Feb 8;22(4):1695. doi: 10.3390/ijms22041695. PMID: 33567580.

Kactus Biosystems Co.Ltd
Online Message